Abstract
Background: Hexavalent chromium (Cr(VI)) is a well-established environmental and occupational toxicant. Following cellular uptake and intracellular reduction, Cr(VI) can generate reactive intermediates that promote oxidative and genotoxic injury, mitochondrial dysfunction, and epigenetic alterations, providing mechanistic pathways potentially relevant to thyroid vulnerability. Aim: This narrative review examines evidence linking species-characterized Cr(VI), or total chromium where valence is unresolved, with thyroid functional, structural, and tissue-injury outcomes across human and experimental models. It also evaluates systemic and multi-omics biomarkers as candidates for future thyroid-focused validation. Methods: Evidence was critically synthesized across human Cr(VI) biomonitoring studies, experimental thyroid toxicology, chromium-related omics investigations, and translational thyroid biomarker research using an evidence-stratified framework that distinguishes direct evidence from mechanistic support and translational inference. Results: Human studies support Cr(VI)-associated oxidative DNA damage, altered mitochondrial indices, selected epigenetic changes, and systemic perturbations in lipid-, amino-acid-, nucleotide-, and steroid-related metabolic pathways. Human studies have related total chromium to thyroid hormones or tumor characteristics without resolving chromium valence. Experimental studies demonstrate thyroid hormonal imbalance, oxidative and inflammatory injury, DNA damage, and histopathological alterations. Broader thyroid multi-omics research identifies metabolomic, circulating nucleic acid, mitochondrial, non-coding RNA, and extracellular-vesicle markers with translational potential; however, these markers have not been validated as indicators of chromium-specific thyroid toxicity. Conclusions: Current evidence supports a biologically coherent but incomplete exposure-to-effect framework linking Cr(VI) with molecular processes relevant to thyroid vulnerability, without establishing a direct causal relationship with human thyroid dysfunction or thyroid cancer. Recommendations: Prospective human studies integrating chromium exposure assessment, thyroid function, and harmonized multi-omics profiling are required to validate mechanistically informed biomarker panels.
1. Introduction
Hexavalent chromium (Cr(VI)) is a well-established environmental and occupational toxicant with genotoxic and carcinogenic properties. Human exposure occurs in occupational settings involving chromate production, electroplating, welding, stainless-steel processing, leather tanning, and pigment-related industries, as well as through environmental contamination of water, soil, and dust. Following cellular uptake through endogenous anion transport systems, Cr(VI) undergoes intracellular reduction through intermediate oxidation states to Cr(III). This process generates reactive intermediates and oxidative stress capable of damaging DNA and proteins, disrupting mitochondrial function, and altering redox-sensitive cellular signaling [1,2,3,4,5]. The thyroid is a biologically plausible target of such disturbances because thyroid hormone synthesis requires tightly regulated oxidative reactions and redox homeostasis [6]. However, the available evidence must be separated according to its biological specificity. Human Cr(VI) biomonitoring studies demonstrate systemic oxidative DNA damage, altered mitochondrial indices, selected epigenetic changes, and metabolic remodeling [7,8], but these findings are not validated thyroid-specific biomarkers. In contrast, experimental rat studies provide more direct evidence of thyroid toxicity. Potassium dichromate exposure has been associated with altered thyroid hormone homeostasis, oxidative and inflammatory injury, DNA damage, and histopathological follicular changes [9,10]. Human studies have measured total chromium alongside thyroid hormones and thyroid cancer characteristics [11,12,13]. Their exposure measurements do not isolate the contribution of Cr(VI). Multi-omics approaches provide an additional opportunity to characterize the biological response to chromium exposure. Human metabolomics studies indicate alterations in lipid, amino acid, nucleotide, and related metabolic pathways following environmental or occupational chromium exposure [8,14,15]. In parallel, the broader thyroid biomarker literature has identified metabolomic signatures, circulating nuclear and mitochondrial DNA, non-coding RNAs, mitochondrial markers, and extracellular-vesicle cargo as candidate diagnostic or stratification tools [16,17,18,19,20]. These thyroid-derived biomarkers do not constitute evidence of chromium-specific thyroid disease; rather, they provide translational models for future evaluation in appropriately characterized Cr(VI)-exposed populations. The novelty of this review lies in its evidence-stratified integration of four previously fragmented evidence domains: human Cr(VI) biomonitoring [7], direct experimental thyroid toxicity [9,10,21,22,23], chromium-related multi-omics responses [8,14,15], and translational thyroid biomarker research [16,17,18,19,20,24]. Rather than treating these evidence streams as equivalent, we distinguish direct human and thyroid-specific evidence from mechanistic support and translational inference. This exposure-to-effect framework enables candidate biomarkers to be positioned according to their biological role and evidentiary strength, from internal exposure and early molecular effects to thyroid-relevant outcomes and future clinical translation.
Accordingly, this review critically integrates human biomonitoring, experimental thyroid toxicology, chromium-related multi-omics, and translational thyroid biomarker evidence within an exposure-to-effect framework [7,8,9,10,16,17,18,24]. We distinguish biomarkers of exposure and early biological effect from thyroid-specific and clinically oriented candidates, while explicitly separating direct evidence from mechanistic and translational inference. The review further identifies the principal validation gaps that must be addressed before Cr(VI)-related multi-omics signatures can support thyroid-focused biomonitoring or risk assessment. The primary objective is to critically evaluate whether measured chromium exposure, identified as Cr(VI) where possible and as total chromium otherwise, is linked to thyroid functional endpoints (TSH, FT4, and FT3), thyroid follicular histopathology, iodine-organification outcomes, or thyroid-tissue oxidative/genotoxic injury across human observational studies, in vivo animal models, and in vitro/ex vivo systems. The secondary objectives are to synthesize systemic early-effect and multi-omics findings, distinguish chromium-associated signals from thyroid disease biomarkers lacking exposure data, and identify priorities for prospective validation. Building on reviews of chromium toxicity [1,4,5] and thyroid biomarker discovery [18,24], we propose that systemic oxidative injury may precede changes in thyroid function. Testing this hypothesis requires repeated measurements of exposure, molecular response, and thyroid function in the same individuals.
Methods of the Narrative Review
We identified relevant publications through searches of PubMed, Google Scholar, Scopus, ScienceDirect, and Web of Science. This narrative review draws on representative publications in four areas: human biomonitoring of chromium exposure, experimental studies of thyroid effects, chromium-related omics studies, and thyroid biomarker research. We interpreted each publication according to the exposure and outcome it assessed. For example, studies of thyroid disease without chromium measurements informed the choice of candidate biomarkers for future research. Representative studies from these domains are discussed and compared in Section 2.
Search concepts. The search concepts covered chromium exposure (chromium, hexavalent chromium, Cr(VI), chromate, and dichromate), thyroid structure and function (thyroid, TSH, FT4, FT3, thyroid follicles, and iodine organification), and complementary molecular domains (biomonitoring, oxidative stress, DNA methylation, metabolomics, multi-omics, circulating DNA, non-coding RNAs, and extracellular vesicles). Appendix A gives illustrative platform-specific search expressions for the human chromium–thyroid component, rather than a preserved record of every search carried out.
We considered English-language publications published through July 2026. Given the limited literature directly examining chromium exposure and thyroid outcomes together, we imposed no lower publication-year limit. The cited publications span 1974–2026. We organized the narrative synthesis by the exposure-characterized biological system and endpoint measured. Evidence of a human exposure–thyroid relationship requires both an exposure measure and a thyroid endpoint in the same participants. A controlled chromium challenge with a thyroid endpoint provides experimental evidence within that model. Human chromium studies with systemic endpoints provide evidence of systemic response. Thyroid disease studies without chromium assessment inform assay selection only. Reports outside these categories can inform background physiology or methods but do not contribute evidence of a chromium–thyroid association. These categories describe what a study can address and do not constitute a formal risk-of-bias rating. The review draws on a purposive selection of reports relevant to its four evidence domains. For the human thyroid question, we distinguished studies that measured chromium and a thyroid endpoint in the same participants from studies contributing mechanistic context or candidate assays. Total chromium studies were considered separately from studies with species-characterized exposure.
The inclusion criteria we considered were (i) human observational studies measuring chromium and thyroid functional, morphological, or disease-related endpoints in the same participants, (ii) in vivo animal studies administering defined chromium compounds and assessing thyroid hormones, tissue morphology, or thyroid injury, (iii) in vitro or ex vivo experimental systems examining chromium-related thyroid or mechanistic endpoints, (iv) human chromium biomonitoring or omics studies reporting systemic early-effect biomarkers, and (v) thyroid biomarker research without chromium assessment, used only to identify candidate assays for subsequent exposure-focused validation. Exposure species, route, dose or concentration, timing, biological matrix, model, and endpoints were considered as relevant. No single exposure-window restriction was imposed across these heterogeneous study designs.
The exclusion criteria were non-English reports and publications after July 2026, which were outside the stated review scope. Studies without a chromium measure were not treated as evidence of a chromium–thyroid association, and chromium studies without a thyroid-specific endpoint were not treated as evidence of thyroid injury. General toxicology reviews, thyroid disease biomarker studies, and methodological papers could inform biological context, assay choice, or interpretation but not direct exposure–thyroid inference. These were criteria for evidentiary relevance within a narrative synthesis, not retrospectively applied eligibility filters from an exhaustive systematic-screening protocol.
Study identification and synthesis were purposive and relevance-based, rather than based on an exhaustive record-by-record screening process. A standardized log of records identified, screened, and excluded was not maintained. Retrospective numerical selection metrics or a PRISMA-style flow diagram would, therefore, imply a process that was not performed.
2. Chromium Exposure, Thyroid Outcomes, and Biomarker Evidence
2.1. Cr(VI) Toxicokinetics and Systemic Early-Effect Biomarkers
Following cellular uptake, Cr(VI) undergoes intracellular reduction through reactive intermediate oxidation states to Cr(III), generating oxidative and genotoxic stress and perturbing cellular redox homeostasis. These processes can damage DNA and proteins and affect mitochondrial function, providing a mechanistic basis for early biological effects measurable before overt disease develops [1,2,3,4,5]. Human biomonitoring provides the strongest direct evidence for these early systemic effects. In the SafeChrom study, occupational Cr(VI) exposure was characterized using inhalable Cr(VI) together with total chromium in urine and red blood cells. Exposed workers showed higher urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG), longer relative telomere length, increased MGMT promoter methylation, and lower blood mitochondrial DNA copy number compared with controls [7]. Importantly, these endpoints were measured in accessible biological matrices and should be interpreted as systemic biomarkers of exposure-related biological effect rather than as thyroid-specific biomarkers. The direction and clinical significance of the telomere finding also remain uncertain and should not be interpreted as a unidirectional marker of toxicity.
Mitochondrial disturbance is biologically consistent with experimental evidence showing that Cr(VI) can impair mitochondrial bioenergetics and alter mitochondrial adaptive responses. Experimental studies have demonstrated inhibition of mitochondrial respiration and phosphorylation efficiency, while cellular models show concentration-dependent alterations in mitochondrial biogenesis and related regulatory pathways [25,26]. More recent review-level evidence further supports effects of Cr(VI) on oxidative phosphorylation, mitophagy, and mitochondrial biogenesis [27]. These findings provide mechanistic support for the reduced blood mtDNA copy number observed in exposed workers, but they do not establish thyroid-specific mitochondrial injury.
Human metabolomics studies extend the evidence from molecular damage to systemic biochemical remodeling. In residents exposed to Cr(VI) through drinking water, urinary metabolomics identified differential metabolites and perturbations involving steroid synthesis, androgen and estrogen metabolism, arginine and proline metabolism, and purine and pyrimidine pathways [15]. Occupational studies similarly identified changes in urinary metabolic profiles [14] and serum metabolites, particularly in arginine/proline and glycerophospholipid metabolism [8]. These findings should nevertheless be interpreted cautiously: Kozłowska et al. [14] noted that some observed metabolic differences could reflect work-related factors other than Cr(VI), whereas Long et al. [8] identified diet as a potential uncontrolled confounder.
Table 1 summarizes the biomarker domains and the evidence supporting them. The human studies identify systemic oxidative, mitochondrial, epigenetic, telomere-related, and metabolic responses [7,8,14,15]. Their designs leave open whether these responses precede a change in thyroid function.
Table 1.
Evidence-stratified biomarker domains relevant to Cr(VI) exposure and thyroid vulnerability.
Table 2 provides a chronological summary of representative studies underpinning the evidence framework of this review.
Table 2.
Chronological summary of representative studies underpinning the evidence framework of this review.
2.2. Redox-Driven Cellular Dysfunction, Inflammation, and Direct Thyroid Injury
Oxidative stress provides the clearest mechanistic link between Cr(VI) exposure and experimentally observed thyroid injury. Intracellular reduction of Cr(VI) generates reactive intermediates and disrupts cellular redox homeostasis, whereas normal thyroid hormone synthesis itself depends on tightly regulated oxidative processes. The thyroid is, therefore, biologically susceptible to disturbances that shift physiological oxidant signaling toward sustained oxidative damage [5,6]. This susceptibility is supported by Gładysz et al., 2026 [21], who demonstrated in porcine tissue homogenates that Cr(VI) induced lipid peroxidation at substantially lower concentrations than Cr(III), with pronounced oxidative effects in thyroid tissue. Importantly, this study was conducted in vitro and did not assess thyroid hormones, DNA damage, or histopathology [21].
More direct evidence of functional thyroid toxicity comes from experimental rat studies. In male rats exposed to potassium dichromate, Mohamed and Abd El-Twab, 2016 [9] reported decreased serum FT3 and FT4, increased TSH, impaired antioxidant defenses, enhanced nitrosative and inflammatory signaling, and thyroid histopathological alterations. Reported morphological changes included distended, collapsed, and degenerated follicles with vacuolated cytoplasm. Gallic acid co-treatment attenuated several of the reported oxidative and inflammatory effects [9]. These findings provide direct experimental evidence that chromium exposure can disrupt thyroid hormone homeostasis and tissue integrity. Gallic acid co-treatment also improved follicular morphology, as shown by histological examination [9].
Complementary evidence is provided by Fedala et al., 2021 [10], who examined potassium-dichromate-induced thyrotoxicity in pregnant Wistar rats. Exposure produced hypothyroidism, oxidative stress, DNA damage, and histological alterations of the thyroid gland. Selenium or zinc co-treatment mitigated several of these effects through antioxidant and genoprotective actions, although combined supplementation was not uniformly more protective [10]. This study, therefore, strengthens the evidence for oxidative and genotoxic mechanisms in experimental Cr(VI)-induced thyroid injury while also illustrating the importance of antioxidant status as a potential modifier of toxicity. Exposure on gestational day 3 identifies early pregnancy as a window for studying maternal susceptibility. Without a matched nonpregnant group or offspring follow-up, this experiment cannot establish greater susceptibility during pregnancy or persistent effects in offspring. Extending the result to nonpregnant workers would also require accounting for route, dose, and exposure duration.
These findings are mechanistically consistent with the redox dependence of normal thyroid physiology. Thyroid hormone biosynthesis requires controlled hydrogen-peroxide generation and thyroid peroxidase-dependent oxidation, while endogenous antioxidant systems protect thyrocytes from excessive oxidative damage [6]. However, the available chromium studies do not establish direct inhibition of specific thyroid components, such as the sodium-iodide symporter, DUOX enzymes, or thyroid peroxidase. These pathways should, therefore, be regarded as biologically relevant targets for future investigation rather than demonstrated molecular targets of Cr(VI).
Two experiments help distinguish effects in thyroid tissue from whole-body hormonal regulation. In bovine thyroid slices, sodium chromate increased iodine incorporation into organic material and altered the glutathione system [22]. This establishes an effect on iodination under the assay conditions. It does not identify direct inhibition of thyroid peroxidase or transport through the sodium-iodide symporter. In an acute rat model, chromium increased in the hypothalamus but decreased in the thyroid despite follicular hyperplasia and lower circulating FT4 and FT3 [23]. The tissue measurements did not resolve chromium valence or uptake into individual thyrocytes. The findings challenge a simple accumulation model and leave open contributions from central regulation, thyroid injury, and peripheral hormone metabolism. Paired measurements of thyroid chromium, iodide uptake, peroxidase activity, and deiodinase activity over time would help distinguish these mechanisms.
Human studies address parts of the exposure–thyroid question. In Spanish male adolescents, higher urinary chromium was associated with lower serum TSH in a cross-sectional analysis [11]. In a prospective pregnancy study in Shanghai, a first-trimester mixture of seven elements was associated with higher third-trimester total T3, and chromium contributed to the mixture estimate [12]. Neither result identifies a Cr(VI)-specific effect. Hu et al. assessed urinary elements in 608 patients already diagnosed with papillary thyroid carcinoma [13]. Their case-only comparison addressed tumor characteristics and could not estimate cancer incidence. A scoping review of seven human studies examining chromium and thyroid hormones identified two with statistically significant associations and five without [33]. The reported directions differed: lower TSH with urinary chromium in adolescents and higher TSH with blood chromium during a low-exposure period in another population. These populations, exposure metrics, and endpoints differ too substantially to infer a common direction of thyroid response. The evidence gap concerns species-characterized exposure measured alongside thyroid outcomes, rather than the existence of human chromium–thyroid studies.
Table 3 compares thyroid experiments by exposure, endpoint, and inference. Injected doses refer to the administered compound per kilogram of body weight. Concentrations applied directly to tissue are presented separately. For context, SafeChrom workers had a median inhalable Cr(VI) concentration of 0.11 µg/m3 [7]. Air concentration, an injected compound dose per kilogram, and a concentration applied directly to a homogenate describe distinct exposures. Translating among them would require route-specific uptake and thyroid dosimetry.
Table 3.
Experimental evidence linking chromium exposure to thyroid outcomes.
2.3. Genomic Instability, Epigenetic Dysregulation, and Senescence-Related Mechanisms
Cr(VI) genotoxicity extends beyond oxidative stress and includes direct interference with genomic integrity. Following intracellular reduction, chromium-derived species can form DNA adducts and generate secondary lesions that interfere with replication and DNA repair processes [1,4,34]. Current mechanistic evidence, therefore, supports genomic instability as a relevant early biological-effect domain of Cr(VI) toxicity, although these effects are not thyroid specific.
Human evidence also supports chromium-associated epigenetic alteration. In the SafeChrom occupational study, Jiang et al., 2025 [7] reported increased MGMT promoter methylation in Cr(VI)-exposed workers together with oxidative DNA damage and altered mitochondrial- and telomere-related indices. This finding is biologically relevant because MGMT is involved in DNA damage repair; however, the current human evidence supports MGMT methylation as an exposure-associated molecular signal rather than as a validated thyroid or cancer biomarker. Accordingly, we do not infer that Cr(VI)-induced MGMT methylation directly mediates thyroid carcinogenesis.
Environmental evidence is provided by Zhao et al., 2023 [28], who conducted an epigenome-wide analysis in 20 individuals from a chromium-contaminated and a comparison area. Five CpG sites associated with urinary chromium survived false-discovery-rate correction. The study also identified a differentially methylated region annotated to ALDH3A1. The study is important because it demonstrates an environmental chromium-associated DNA-methylation signal in humans, but its small sample size and cross-sectional design require cautious interpretation [28].
Chromatin-level regulation provides an additional mechanistic dimension. Zablon et al., 2019 [31] reviewed evidence that Cr(VI) can disrupt chromatin architecture and transcriptional regulation through interactions among DNA damage, epigenetic changes, and altered access of the transcriptional machinery. These findings support regulatory reprogramming as part of chromium toxicity, but they remain mechanistic and are not evidence of a thyroid-specific epigenetic pathway [31].
Cellular senescence has recently emerged as a further exposure-related response. In Ji et al., 2025 [32], 304 workers from a chromate facility were evaluated together with a chromate-inhalation mouse model. In workers, blood chromium was associated with p53 and with methylation changes involving hTERT and ELOVL2, while hTERT methylation partially mediated the association between chromium and p53. In mice, chromate exposure increased senescence-associated β-galactosidase positivity and activated the p53/p21 and Rb/p16 pathways [32]. These findings provide comparatively strong evidence that cellular senescence is relevant to chronic Cr(VI) exposure, but the measured endpoints remain systemic and not thyroid specific.
Taken together, the most defensible current interpretation is that Cr(VI) exposure is associated with genomic damage, selected DNA-methylation changes, chromatin dysregulation, and senescence-related responses. These domains may be relevant to long-term cellular vulnerability and carcinogenesis-related processes; however, their relevance to human thyroid carcinogenesis remains unestablished. Their present value, therefore, lies in mechanistic interpretation and biomarker hypothesis generation rather than in thyroid-specific clinical prediction.
2.4. Multi-Omics and Translational Thyroid Biomarker Candidates
Human total chromium studies address thyroid outcomes [11,12,13], while occupational Cr(VI) studies establish systemic molecular responses [7,8,14]. The studies summarized here do not validate a molecular signature of thyroid injury attributable to Cr(VI) in exposed people. Thyroid disease cohorts provide a separate source of candidate assays, whose performance must be tested for this exposure-specific purpose.
Four indicators answer different questions. A measurement of inhalable Cr(VI) characterizes external exposure, and total chromium in urine or blood describes internal chromium burden [7]. Urinary 8-OHdG or blood mitochondrial DNA copy number can identify an early systemic response [7]. Serum TSH and FT4 measure thyroid function, but a change in either requires evaluation of other causes [9,10]. Finally, a tumor diagnostic marker is evaluated against a disease comparator, such as malignant versus benign nodules [17]. Its performance in that comparison says nothing about its sensitivity to early injury in an exposed person without a tumor.
Metabolomics represents one of the most developed translational domains. Yu et al., 2022 [17] evaluated plasma metabolomic profiles in two independent cohorts comprising 651 individuals with papillary thyroid carcinoma (PTC), benign thyroid nodules, or healthy controls. A 17-metabolite panel discriminated PTC from benign nodules with high performance in both discovery and validation cohorts, demonstrating the potential of metabolomic signatures for clinically relevant thyroid-nodule classification [17]. Complementary evidence from Du et al., 2021 [29], involving 80 patients with PTC and 80 healthy controls, identified 64 differential serum metabolites and 8 altered metabolic pathways, although this comparison addressed cancer versus healthy controls rather than the more clinically challenging distinction between malignant and benign nodules [29].
Occupational studies identify exposure-associated changes in serum and urinary metabolites [8,14], whereas the plasma panel reported by Yu et al. discriminated between thyroid disease categories [17]. A prospective study could test whether selected metabolites change with exposure before a change in thyroid function.
Circulating DNA and mitochondrial biomarkers provide a second translational domain. Perdas et al., 2019 [16] examined plasma from patients with papillary thyroid carcinoma and reported higher circulating nuclear-cell-free DNA together with lower circulating mitochondrial DNA compared with healthy controls. The study was exploratory and included only 32 patients, but it supports the potential utility of circulating nuclear and mitochondrial DNA as thyroid disease biomarkers [16]. Broader thyroid literature further supports mitochondrial alterations as a relevant molecular domain [16,35]. These observations align conceptually with Cr(VI)-associated mitochondrial perturbation, but they do not demonstrate that chromium exposure produces the same circulating DNA profile in human thyroid disease.
Reviews of thyroid neoplasia identify microRNAs, long non-coding RNAs, and circular RNAs as potential diagnostic or prognostic markers [18]. Their performance in Cr(VI)-exposed populations remains an open question.
Extracellular vesicles (EVs) carry nucleic acids, proteins, and other molecular cargo involved in intercellular communication [19]. Ahmed et al. reviewed 40 studies of EV-associated biomarkers in thyroid cancer, including miRNAs and proteins [20]. These studies provide candidates for exploratory assays in exposed cohorts, although their patient populations cannot establish an association with chromium exposure.
More broadly, thyroid multi-omics research demonstrates how metabolomic, genomic, mitochondrial, transcriptomic, proteomic, and EV-derived information may be combined to improve biological interpretation and diagnostic stratification [24,30]. For Cr(VI)-related thyroid research, the priority is not to transfer existing thyroid disease signatures directly into exposed populations, but to test whether exposure-associated molecular changes co-occur with thyroid functional endpoints in well-characterized human cohorts.
For a first prospective study, we would prioritize urinary 8-OHdG and blood mitochondrial DNA copy number because both differed between exposed workers and controls in SafeChrom [7]. Repeated measurements alongside serum TSH and FT4 would allow investigators to test whether changes in either systemic marker precede changes in thyroid function. TSH and FT4 would serve as functional outcomes, given the hormonal changes observed in exposed rats [9,10]. A second priority is targeted replication of metabolites from occupational studies [8,14], using the same specimen type as the discovery study. EV cargo and circulating cell-free DNA merit exploratory analysis because their supporting human evidence comes chiefly from patients with thyroid disease [16,19,20].
2.5. Clinical Utility, Analytical Validation, and Implementation Challenges
Identification of a biologically plausible biomarker does not by itself establish clinical or public-health utility. In the Cr(VI)-thyroid context, three evidentiary levels should remain distinct: markers of internal exposure, systemic markers of early biological effect, and candidate thyroid-oriented biomarkers. Human Cr(VI) studies currently provide evidence mainly for the first two levels, including chromium measurements in biological matrices and molecular endpoints, such as oxidative DNA damage, mitochondrial indices, DNA methylation, and metabolomic perturbations [7,8]. By contrast, thyroid-focused omics markers remain translational candidates and have not been validated for Cr(VI)-specific thyroid assessment.
Analytical reproducibility and pre-analytical standardization are central barriers to translation. Omics measurements can be influenced by sample collection, processing, storage, normalization, analytical platform, and quality-control procedures. Siskos et al., 2017 [36], for example, demonstrated that targeted metabolomics can achieve substantial interlaboratory reproducibility when a common analytical protocol and standardized quality-control procedures are applied across laboratories [36]. Similarly, Canzler et al., 2025 [30] emphasized the importance of experimental design, data quality, and appropriate integration strategies when combining multiple omics layers in toxicological research [30]. These considerations are particularly important before exploratory multi-omics signals can be translated into reproducible targeted biomarker assays.
Chromium redox chemistry complicates exposure interpretation [37]. Personal air sampling can measure inhalable Cr(VI) over the monitored shift but cannot quantify absorbed dose. Total chromium in urine reflects recent exposure and depends on collection timing and dilution. Plasma chromium reflects recent circulating chromium and can include contributions from either valence state. In contrast, Cr(VI) can enter erythrocytes through anion transporters, whereas Cr(III) enters poorly. Reduction and trapping inside the cell make erythrocyte total chromium a relatively specific marker of absorbed Cr(VI) reaching the blood. Its retention integrates exposure over weeks to months (estimated half-life about 63 days); it measures retained chromium, not circulating intact Cr(VI) or thyroid dose. Reduction before erythrocyte uptake, exposure intensity, and work process can affect its sensitivity [7,38]. Two participants with similar total urinary chromium may have different Cr(VI) exposures. Grouping them together can obscure an exposure–response gradient, and an association with total chromium alone cannot establish which chromium species contributed to it. Where feasible, personal airborne Cr(VI) measurements or species-specific measurements in the relevant source should accompany biomonitoring [7].
In SafeChrom, investigators measured Cr(VI) in inhalable dust and total chromium in urine and red blood cells [7]. The drinking-water study concerns ingestion [15], whereas the environmental methylation study related its findings to urinary chromium [28]. These measures represent different quantities. A spot urine concentration does not provide a cumulative dose or reconstruct the duration of exposure. Neither the injected compound doses nor the tissue incubation concentrations in Table 3 can be converted to equivalent human airway, drinking-water, or thyroid exposures from the data reported. These studies, therefore, support qualitative comparisons of response patterns, but not a common quantitative dose–response estimate.
Study design also limits current translational interpretation. Many available exposure studies are cross-sectional, whereas several thyroid biomarker studies are exploratory case-control investigations. Co-exposures, smoking, diet, micronutrient status, inflammation, and other biological or environmental factors may influence molecular endpoints independently of chromium exposure. Moreover, candidate omics biomarkers generally lack validated thresholds for chromium-related thyroid risk. Accordingly, associations identified in discovery datasets should not be considered clinically predictive until they are replicated in independent cohorts and evaluated alongside direct thyroid functional endpoints.
Artificial intelligence and computational integration may assist in handling high-dimensional multi-omics data, but they do not compensate for weak exposure assessment or limited validation. General multi-omics research indicates that machine learning approaches can support feature integration and biomarker discovery [39], while thyroid-focused literature describes applications of machine learning and deep learning approaches to thyroid disease classification [40]. These studies support the methodological potential of computational approaches but provide no evidence that an AI-derived Cr(VI)-thyroid biomarker model has already been validated. Computational models should, therefore, be treated as analytical tools whose performance requires independent validation, biological interpretability, and assessment of transferability across populations and platforms.
Adverse outcome pathway (AOP) principles may also provide a useful organizational framework for future mechanistic integration. AOP methodology is designed to connect molecular initiating events, intermediate key events, and adverse outcomes in a structured and evidence-based manner [41]. However, the literature evaluated in this review does not establish a validated Cr(VI)-to-thyroid AOP. Oxidative, mitochondrial, genomic, epigenetic, and inflammatory responses should, therefore, be considered candidate mechanistic domains for future AOP development rather than formally established key events in a validated thyroid-specific pathway.
Overall, translation will require prospective human studies with well-characterized exposure, harmonized biospecimen and analytical protocols, independent replication, control of relevant confounders, and concurrent assessment of thyroid function. The near-term objective should, therefore, be validation of mechanistically informed biomarker combinations rather than adoption of a single diagnostic marker or unvalidated multi-omics classifier.
3. Future Directions and Research Priorities
Future research should prioritize prospective human studies that assess chromium exposure, thyroid function, and molecular responses within the same individuals. Studies of thyroid hormones and total chromium [11,12] and occupational studies with species-characterized exposure [7] provide complementary starting points. Longitudinal designs incorporating internal chromium metrics, thyroid hormones (TSH, FT4, and, where appropriate, FT3), relevant clinical phenotyping, and repeated multi-omics measurements would help establish temporality and distinguish transient biological responses from persistent thyroid-relevant alterations [7,42,43].
Exposure characterization must also be strengthened. Future studies should document exposure source and duration, biological matrix, occupational or environmental context, and relevant co-exposures. Smoking, diet, micronutrient status, metabolic characteristics, inflammation, and other environmental exposures should be measured and considered analytically rather than assumed to represent chromium-specific effects. This broader exposome perspective is particularly important when interpreting molecular signatures that may respond to multiple environmental or physiological influences [42,43].
Analytical harmonization and independent validation are equally important. Standardized biospecimen collection, processing, quality-control procedures, and platform-specific normalization are required before discovery-phase omics findings can be compared across studies or translated into targeted assays [30,36]. Candidate biomarker panels should be replicated in independent populations and evaluated against conventional thyroid endpoints before any clinical or risk-prediction role is considered.
Finally, computational and mechanistic integration should be used to organize, rather than overinterpret, emerging evidence. Multi-omics and machine learning approaches may assist in identifying reproducible combinations of exposure and response markers, whereas AOP principles may help position these signals along an exposure-to-effect continuum [39,41]. However, neither an AI-based Cr(VI)-thyroid classifier nor a validated Cr(VI)-to-thyroid AOP currently exists. The immediate research priority is, therefore, the development and validation of evidence-based biomarker architectures that combine exposure assessment, systemic early-effect markers, and direct thyroid functional outcomes.
4. Conclusions
Current evidence supports a biologically coherent but incomplete framework linking Cr(VI) exposure to thyroid vulnerability through oxidative, mitochondrial, genomic/epigenetic, inflammatory, and metabolic perturbations. Human studies report associations of total chromium with thyroid outcomes, while occupational Cr(VI) studies document systemic responses. Experimental studies connect a known chromium compound to measured hormonal or structural changes under defined conditions. Accordingly, available biomarkers should not be interpreted as validated indicators of Cr(VI)-induced thyroid disease, and direct causal relationships with human thyroid dysfunction or thyroid cancer remain unestablished. Future progress requires prospective, well-characterized human studies integrating chromium exposure assessment, thyroid function, and harmonized multi-omics profiling to validate mechanistically informed biomarker panels.
Author Contributions
M.-N.G., conceptualization, methodology, investigation, writing—original draft; C.G., writing—review and editing, validation; D.I., investigation, resources, data curation; D.S., supervision, conceptualization, writing—review and editing; T.P., supervision. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
No new data were created or analyzed in this study. Data sharing is not applicable to this article.
Conflicts of Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Appendix A. Example Searches for Human Studies of Chromium and Thyroid Outcomes
For readers seeking literature on the human thyroid question, the examples below translate the review concepts into platform-specific queries. They are illustrative search expressions. Apply an English-language restriction and a publication cutoff of July 2026, with no lower year limit. Where an interface offers year-only filters, check individual 2026 publication dates against the July cutoff.
PubMed: (chromium[tiab] OR chromate*[tiab] OR dichromate*[tiab]) AND (thyroid*[tiab] OR thyrotropin[tiab] OR thyroxine[tiab] OR triiodothyronine[tiab]) AND english[lang] AND (“1000/01/01”[dp]: “2026/07/31”[dp]).
Scopus: TITLE-ABS-KEY((chromium OR chromate* OR dichromate*) AND (thyroid* OR thyrotropin OR thyroxine OR triiodothyronine)).
Web of Science Core Collection: TS = ((chromium OR chromate* OR dichromate*) AND (thyroid* OR thyrotropin OR thyroxine OR triiodothyronine)).
ScienceDirect: in title, abstract, or author keywords, enter (chromium OR chromate OR dichromate) AND (thyroid OR thyrotropin OR thyroxine OR triiodothyronine).
Google Scholar: run shorter searches separately, including “urinary chromium” thyroid, “blood chromium” thyroid, and “hexavalent chromium” “thyroid cancer”.
References
- Salnikow, K.; Zhitkovich, A. Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: Nickel, arsenic, and chromium. Chem. Res. Toxicol. 2008, 21, 28–44. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- O’Brien, T.J.; Ceryak, S.; Patierno, S.R. Complexities of chromium carcinogenesis: Role of cellular response, repair and recovery mechanisms. Mutat. Res. 2003, 533, 3–36. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhitkovich, A. Importance of chromium-DNA adducts in mutagenicity and toxicity of chromium(VI). Chem. Res. Toxicol. 2005, 18, 3–11. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Krawic, C.; Zhitkovich, A. Chemical mechanisms of DNA damage by carcinogenic chromium(VI). Adv. Pharmacol. 2023, 96, 25–46. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Singh, V.; Singh, N.; Verma, M.; Kamal, R.; Tiwari, R.; Chivate, M.S.; Rai, S.N.; Kumar, A.; Singh, A.; Singh, M.P.; et al. Hexavalent-chromium-induced oxidative stress and the protective role of antioxidants against cellular toxicity. Antioxidants 2022, 11, 2375. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kochman, J.; Jakubczyk, K.; Bargiel, P.; Janda-Milczarek, K. The influence of oxidative stress on thyroid diseases. Antioxidants 2021, 10, 1442. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Jiang, Z.; Runkel, A.; Lindh, C.; Kukka, A.; Catalán, J.; Pineda, D.; Lundh, T.; Vogel, U.; Saber, A.T.; Tondel, M.; et al. Oxidative damage, genetic and epigenetic alterations in hexavalent chromium exposed workers: A cross-sectional study within the SafeChrom project. Environ. Res. 2025, 283, 122123. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Long, C.; Hu, G.; Zheng, P.; Chen, T.; Su, Z.; Zhang, Y.; Ding, C.; Peng, F.; Yu, S.; Wang, T.; et al. Analysis of serum metabolome of workers occupationally exposed to hexavalent chromium: A preliminary study. Toxicol. Lett. 2021, 349, 92–100. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mohamed, H.M.; Abd El-Twab, S.M. Gallic acid attenuates chromium-induced thyroid dysfunction by modulating antioxidant status and inflammatory cytokines. Environ. Toxicol. Pharmacol. 2016, 48, 225–236. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Fedala, A.; Adjroud, O.; Abid-Essefi, S.; Timoumi, R. Protective effects of selenium and zinc against potassium dichromate-induced thyroid disruption, oxidative stress, and DNA damage in pregnant Wistar rats. Environ. Sci. Pollut. Res. Int. 2021, 28, 22563–22576. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Castiello, F.; Olmedo, P.; Gil, F.; Molina, M.; Mundo, A.; Romero, R.R.; Ruíz, C.; Gómez-Vida, J.; Vela-Soria, F.; Freire, C. Association of urinary metal concentrations with blood pressure and serum hormones in Spanish male adolescents. Environ. Res. 2020, 182, 108958. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wu, T.; Li, T.; Zhang, C.; Hao, Y.H.; Zhang, S.W.; Wang, X.P.; Meng, Y.-C.; Wu, Y.-T.; Huang, H.-F. Effects of maternal trace elements exposure in early pregnancy on maternal thyroid hormones and birth outcomes. Biol. Trace Elem. Res. 2026, 204, 484–494. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Hu, M.J.; He, J.L.; Tong, X.R.; Yang, W.J.; Zhao, H.H.; Li, G.A.; Huang, F. Associations between essential microelements exposure and the aggressive clinicopathologic characteristics of papillary thyroid cancer. Biometals 2021, 34, 909–921. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kozłowska, L.; Santonen, T.; Duca, R.C.; Godderis, L.; Jagiello, K.; Janasik, B.; Van Nieuwenhuyse, A.; Poels, K.; Puzyn, T.; Scheepers, P.T.J.; et al. HBM4EU chromates study: Urinary metabolomics study of workers exposed to hexavalent chromium. Metabolites 2022, 12, 362. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Yanan, T.; Miaomiao, H.; Yunting, X.; Fangda, P.; Chuanlong, X.; Chunguang, D. Urine metabolomic characteristics of people exposed to hexavalent chromium in drinking water. Ecotoxicol. Environ. Saf. 2025, 302, 118670. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Perdas, E.; Stawski, R.; Kaczka, K.; Nowak, D.; Zubrzycka, M. Altered levels of circulating nuclear and mitochondrial DNA in patients with Papillary Thyroid Cancer. Sci. Rep. 2019, 9, 14438. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Yu, S.; Liu, C.; Hou, Y.; Li, J.; Guo, Z.; Chen, X.; Zhang, L.; Peng, S.; Hong, S.; Xu, L.; et al. Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancer. Oncogene 2022, 41, 2422–2430. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Cabané, P.; Correa, C.; Bode, I.; Aguilar, R.; Elorza, A.A. Biomarkers in thyroid cancer: Emerging opportunities from Non-Coding RNAs and mitochondrial space. Int. J. Mol. Sci. 2024, 25, 6719. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Delcorte, O.; Degosserie, J.; Pierreux, C.E. Role of extracellular vesicles in thyroid physiology and diseases: Implications for diagnosis and treatment. Biomedicines 2022, 10, 2585. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ahmed, N.M.; Beatson, K.; Patel, J.; Eddama, M.M.R.; Clapp, L.H.; Abdel-Aziz, T. The diagnostic and prognostic potential of extracellular vesicles as biomarkers for thyroid cancer: A systematic review. J. Mol. Med. 2025, 103, 1333–1372. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Gładysz, A.K.; Stępniak, J.; López-Pingarrón, L.; Garcia, J.J.; Karbownik-Lewińska, M. Stronger prooxidative effects of chromium (VI) comparing to chromium (III) in endocrine and non-endocrine tissues with the thyroid being completely resistant to antioxidant protection. Toxicol. In Vitro 2026, 110, 106132. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Chiraseveenuprapund, P.; Rosenberg, I.N. Observations on the effects of chromate on the thyroid. Endocrinology 1974, 94, 1714–1722. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mahmood, T.; Qureshi, I.Z.; Iqbal, M.J. Histopathological and biochemical changes in rat thyroid following acute exposure to hexavalent chromium. Histol. Histopathol. 2010, 25, 1355–1370. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Piga, I.; L’Imperio, V.; Capitoli, G.; Denti, V.; Smith, A.; Magni, F.; Pagni, F. Paving the path toward multi-omics approaches in the diagnostic challenges faced in thyroid pathology. Expert. Rev. Proteom. 2023, 20, 419–437. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Fernandes, M.A.S.; Santos, M.S.; Alpoim, M.C.; Madeira, V.M.C.; Vicente, J.A.F. Chromium (VI) interaction with plant and animal mitochondrial bioenergetics: A comparative study. J. Biochem. Mol. Toxicol. 2002, 16, 53–63. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhong, X.; Sá, R.D.C.D.S.E.; Zhong, C. Mitochondrial biogenesis in response to chromium (VI) toxicity in human liver cells. Int. J. Mol. Sci. 2017, 18, 1877. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Alur, A.; Phillips, J.; Xu, D. Effects of hexavalent chromium on mitochondria and their implications in carcinogenesis. J. Environ. Sci. Health C Toxicol. Carcinog. 2024, 42, 109–125. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhao, M.; Wu, J.; Xu, J.; Li, A.; Mei, Y.; Ge, X.; Yin, G.; Liu, X.; Wei, L.; Xu, Q. Association of environmental exposure to chromium with differential DNA methylation: An epigenome-wide study. Front. Genet. 2023, 13, 1043486. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Du, Y.; Fan, P.; Zou, L.; Jiang, Y.; Gu, X.; Yu, J.; Zhang, C. Serum metabolomics study of papillary thyroid carcinoma based on HPLC-Q-TOF-MS/MS. Front. Cell Dev. Biol. 2021, 9, 593510. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Canzler, S.; Schubert, K.; Rolle-Kampczyk, U.E.; Wang, Z.; Schreiber, S.; Seitz, H.; Mockly, S.; Kamp, H.; Haake, V.; Huisinga, M.; et al. Evaluating the performance of multi-omics integration: A thyroid toxicity case study. Arch. Toxicol. 2025, 99, 309–332. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zablon, H.A.; VonHandorf, A.; Puga, A. Chromium exposure disrupts chromatin architecture, upsetting the mechanisms that regulate transcription. Exp. Biol. Med. 2019, 244, 752–757. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ji, Z.; Zhang, Y.; Hu, G.; Hong, S.; Su, Z.; Zhang, Q.; Wang, L.; Wang, T.; Yu, S.; Bu, Q.; et al. Hexavalent chromium and cellular senescence: A comprehensive analysis from chromate-exposed occupational population and chromate-inhaled mouse model. J. Hazard. Mater. 2025, 493, 138387. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Rafi’i, M.R.; Ja’afar, M.H.; Nawi, A.M.; Md Hanif, S.A.; Md Asari, S.N. Association between toxic heavy metals and noncancerous thyroid disease: A scoping review. PeerJ 2025, 13, e18962. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wise, S.S.; Wise, J.P., Sr. Chromium and genomic stability. Mutat. Res. 2012, 733, 78–82. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ren, L.; Liu, W.; Zheng, J.; Wu, Q.; Ai, Z. The role of mitochondrial genome stability and metabolic plasticity in thyroid cancer. Biomedicines 2025, 13, 2599. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Siskos, A.P.; Jain, P.; Romisch-Margl, W.; Bennett, M.; Achaintre, D.; Asad, Y.; Marney, L.; Richardson, L.; Koulman, A.; Griffin, J.L.; et al. Interlaboratory reproducibility of a targeted metabolomics platform for analysis of human serum and plasma. Anal. Chem. 2017, 89, 656–665. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bell, J.; Ma, X.; McDonald, T.J.; Huang, C.H.; Sharma, V.K. Overlooked role of chromium (V) and chromium (IV) in chromium redox reactions of environmental importance. ACS ES T Water 2022, 2, 932–942. [Google Scholar] [CrossRef] [Scilit]
- Ndaw, S.; Leso, V.; Bousoumah, R.; Rémy, A.; Bocca, B.; Duca, R.C.; Godderis, L.; Hardy, E.; Janasik, B.; van Nieuwenhuyse, A.; et al. HBM4EU chromates study—Usefulness of measurement of blood chromium levels in the assessment of occupational Cr(VI) exposure. Environ. Res. 2022, 214, 113758. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kant, S.; Deepika Roy, S. Integrative Multi-Omics and Artificial Intelligence: A New Paradigm for Systems Biology. OMICS 2025, 29, 576–587. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Verma, S.; Popli, R.; Kumar, H.; Chaurasia, B.K. AI leveraging solution for thyroid disease: Advances and rationale. Netw. Model. Anal. Health Inform. Bioinform. 2025, 14, 88. [Google Scholar] [CrossRef] [Scilit]
- Tanabe, S.; Burgdorf, T.; Choi, J.; Delrue, N.; Edwards, S.W.; Filipovska, J.; FitzGerald, R.; Halappanavar, S.; Hench, V.K.; Karschnik, T.; et al. Adverse Outcome Pathway (AOP) Coaching Program—How it functions and contributes to a more harmonized approach to AOP development and construction of AOP networks with regulatory utility. Environ. Toxicol. Chem. 2025, 44, 2725–2732. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Sarigiannis, D.; Karakitsios, S.; Anesti, O.; Stem, A.; Valvi, D.; Sumner, S.C.J.; Chatzi, L.; Snyder, M.P.; Thompson, D.C.; Vasiliou, V. Advancing translational exposomics: Bridging genome, exposome and personalized medicine. Hum. Genom. 2025, 19, 48. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Maitre, L.; Bustamante, M.; Hernández-Ferrer, C.; Thiel, D.; Lau, C.H.E.; Siskos, A.P.; Vives-Usano, M.; Ruiz-Arenas, C.; Pelegrí-Sisó, D.; Robinson, O.; et al. Multi-omics signatures of the human early life exposome. Nat. Commun. 2022, 13, 7024. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.